{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:03:11Z","timestamp":1792515791153,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In Diffuse Large B-cell Lymphoma (DLBCL), elevated anti-apoptotic BCL2-family proteins (e.g., MCL1, BCL2, BCLXL) and NF-\u03baB subunits (RelA, RelB, cRel) confer poor prognosis. Heterogeneous expression, regulatory complexity, and redundancy offsetting the inhibition of individual proteins, complicate the assignment of targeted therapy. We combined flow cytometry \u2018fingerprinting\u2019, immunofluorescence imaging, and computational modeling to identify therapeutic vulnerabilities in DLBCL. The combined workflow predicted selective responses to BCL2 inhibition (venetoclax) and non-canonical NF-\u03baB inhibition (Amgen16). Within the U2932 cell line we identified distinct resistance mechanisms to BCL2 inhibition in cellular sub-populations recapitulating intratumoral heterogeneity. Co-cultures with CD40L-expressing stromal cells, mimicking the tumor microenvironment (TME), induced resistance to BCL2 and BCLXL targeting BH3-mimetics via cell-type specific upregulation of BCLXL or MCL1. Computational models, validated experimentally, showed that basal NF-\u03baB activation determined whether CD40 activation drove BH3-mimetic resistance through upregulation of RelB and BCLXL, or cRel and MCL1. High basal NF-\u03baB activity could be overcome by inhibiting BTK to resensitize cells to BH3-mimetics in CD40L co-culture. Importantly, non-canonical NF-\u03baB inhibition overcame heterogeneous compensatory BCL2 upregulation, restoring sensitivity to both BCL2- and BCLXL-targeting BH3-mimetics. Combined molecular fingerprinting and computational modelling provides a strategy for the precision use of BH3-mimetics and NF-\u03baB inhibitors in DLBCL.<\/jats:p>","DOI":"10.1038\/s41419-025-07942-0","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T07:26:51Z","timestamp":1755329211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systems biology-enabled targeting of NF-\u03ba\u0392 and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-8007","authenticated-orcid":false,"given":"Aimilia","family":"Vareli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-0724","authenticated-orcid":false,"given":"Haripriya","family":"Vaidehi Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8043-617X","authenticated-orcid":false,"given":"Heather","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-5414","authenticated-orcid":false,"given":"Eleanor","family":"Jayawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-6212","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9400-6642","authenticated-orcid":false,"given":"Lauren","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-0091","authenticated-orcid":false,"given":"Fabio","family":"Simoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-3845","authenticated-orcid":false,"given":"Alexander","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-1280","authenticated-orcid":false,"given":"Andrea","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-6349","authenticated-orcid":false,"given":"Simon","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"7942_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.12688\/f1000research.22318.1","volume":"9","author":"A Davies","year":"2020","unstructured":"Davies A, Barrans S, Burton C, Mercer K, Caddy J, Chinnery F, et al. ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib\/II open-label non-randomised clinical trial. F1000Res. 2020;9:941.","journal-title":"F1000Res"},{"key":"7942_CR2","first-page":"17515","volume":"8","author":"F Meng","year":"2015","unstructured":"Meng F, Zhong D, Zhang L, Shao Y, Ma Q. Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. Int J Clin Exp Med. 2015;8:17515\u201322.","journal-title":"Int J Clin Exp Med"},{"key":"7942_CR3","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Hoof AV, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326.","journal-title":"J Clin Oncol"},{"key":"7942_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"key":"7942_CR5","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303. J Clin Oncol. 2019;37:1790\u20139.","journal-title":"J Clin Oncol"},{"key":"7942_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s41231-020-00054-1","volume":"5","author":"E Hunter","year":"2020","unstructured":"Hunter E, McCord R, Ramadass AS, Green J, Westra JW, Mundt K, et al. Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies. Transl Med Commun. 2020;5:5.","journal-title":"Transl Med Commun"},{"key":"7942_CR7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"7942_CR8","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","volume":"25","author":"R Vaidya","year":"2014","unstructured":"Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25:2124\u201333.","journal-title":"Ann Oncol"},{"key":"7942_CR9","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cancers12071912","volume":"12","author":"V Priebe","year":"2020","unstructured":"Priebe V, Sartori G, Napoli S, Chung EYL, Cascione L, Kwee I, et al. Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type. Cancers. 2020;12:1912.","journal-title":"Cancers"},{"key":"7942_CR10","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","volume":"131","author":"L Pasqualucci","year":"2018","unstructured":"Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131:2307\u201319.","journal-title":"Blood"},{"key":"7942_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"7942_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/wsbm.1331","volume":"8","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Vargas J, Hoffmann A. Signaling via the NF\u03baB system. WIREs Syst Biol Med. 2016;8:227\u201341.","journal-title":"WIREs Syst Biol Med"},{"key":"7942_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2006.12.033","volume":"128","author":"S Basak","year":"2007","unstructured":"Basak S, Kim H, Kearns JD, Tergaonkar V, O\u2019Dea E, Werner SL, et al. A fourth I\u03baB protein within the NF-\u03baB signaling module. Cell. 2007;128:369\u201381.","journal-title":"Cell"},{"key":"7942_CR14","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.4049\/jimmunol.1302351","volume":"192","author":"BN Alves","year":"2014","unstructured":"Alves BN, Tsui R, Almaden J, Shokhirev MN, Davis-Turak J, Fujimoto J, et al. I\u03baB\u03b5 is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner. J Immunol. 2014;192:3121\u201332.","journal-title":"J Immunol"},{"key":"7942_CR15","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.celrep.2014.11.024","volume":"9","author":"JV Almaden","year":"2014","unstructured":"Almaden JV, Tsui R, Liu YC, Birnbaum H, Shokhirev MN, Ngo KA, et al. A pathway switch directs BAFF signaling to distinct NF\u03baB transcription factors in maturing and proliferating B cells. Cell Rep. 2014;9:2098\u2013111.","journal-title":"Cell Rep"},{"key":"7942_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor \u03baB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861\u201374.","journal-title":"J Exp Med"},{"key":"7942_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12308-009-0021-4","volume":"2","author":"CV Curry","year":"2009","unstructured":"Curry CV, Ewton AA, Olsen RJ, Logan BR, Preti HA, Liu Y-C, et al. Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematopathol. 2009;2:20\u20136.","journal-title":"J Hematopathol"},{"key":"7942_CR18","first-page":"384","volume":"139","author":"B Eluard","year":"2022","unstructured":"Eluard B, Nuan-Aliman S, Faumont N, Collares D, Bordereaux D, Montagne A, et al. The alternative RelB NF-\u03baB subunit is a novel critical player in diffuse large B-cell lymphoma. Blood, J Am Soc Hematol. 2022;139:384\u201398.","journal-title":"Blood, J Am Soc Hematol"},{"key":"7942_CR19","doi-asserted-by":"crossref","unstructured":"Jayawant E, Pack A, Clark H, Kennedy E, Ghodke A, Jones J, et al. NF-\u03baB fingerprinting reveals heterogeneous NF-\u03baB composition in diffuse large B-cell lymphoma. Front Oncol. 2023;13:1181660.","DOI":"10.3389\/fonc.2023.1181660"},{"key":"7942_CR20","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/biomedicines10102450","volume":"10","author":"L Pasqualucci","year":"2022","unstructured":"Pasqualucci L, Klein U. NF-\u03baB mutations in germinal center B-cell lymphomas: Relation to NF-\u03baB function in normal B cells. Biomedicines. 2022;10:2450.","journal-title":"Biomedicines"},{"key":"7942_CR21","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PW Johnson","year":"2023","unstructured":"Johnson PW, Balasubramanian S, Hodkinson B, Shreeve SM, Sun S, Srinivasan S, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7:2008\u201317.","journal-title":"Blood Adv"},{"key":"7942_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"7942_CR23","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41375-018-0128-7","volume":"32","author":"M Studencka-Turski","year":"2018","unstructured":"Studencka-Turski M, Maubach G, Feige MH, Naumann M. Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene. Leukemia. 2018;32:2498\u2013501.","journal-title":"Leukemia"},{"key":"7942_CR24","doi-asserted-by":"crossref","unstructured":"Burley TA, Kennedy E, Broad G, Boyd M, Li D, Woo T, et al. Targeting the non-canonical NF-\u03baB pathway in chronic lymphocytic leukemia and multiple myeloma. Cancers (Basel). 2022;14:1489.","DOI":"10.3390\/cancers14061489"},{"key":"7942_CR25","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","volume":"28","author":"M Haselager","year":"2021","unstructured":"Haselager M, Thijssen R, West C, Young L, Van Kampen R, Willmore E, et al. Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28:1658\u201368.","journal-title":"Cell Death Differ"},{"key":"7942_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.2019001545","volume":"134","author":"TC Froehlich","year":"2019","unstructured":"Froehlich TC, M\u00fcller-Decker K, Braun JD, Albrecht T, Schroeder A, G\u00fclow K, et al. Combined inhibition of Bcl-2 and NF\u03baB synergistically induces cell death in cutaneous T-cell lymphoma. Blood. 2019;134:445\u201355.","journal-title":"Blood"},{"key":"7942_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70\u201380.","journal-title":"Blood"},{"key":"7942_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"7942_CR29","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.3390\/ijms20174133","volume":"20","author":"GC Cavalcante","year":"2019","unstructured":"Cavalcante GC, Schaan AP, Cabral GF, Santana-da-Silva MN, Pinto P, Vidal AF, et al. A Cell\u2019s Fate: An Overview of the Molecular Biology and Genetics of Apoptosis. Int J Mol Sci. 2019;20:4133.","journal-title":"Int J Mol Sci"},{"key":"7942_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10428199909083379","volume":"34","author":"O Monni","year":"1999","unstructured":"Monni O, Franssila K, Joensuu H, Knuutila S. BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma. 1999;34:45\u201352.","journal-title":"Leuk Lymphoma"},{"key":"7942_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600\u20139.","journal-title":"Blood"},{"key":"7942_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"7942_CR33","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk lymphoma. 2017;58:2026\u201339.","journal-title":"Leuk lymphoma"},{"key":"7942_CR34","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3324\/haematol.2019.220525","volume":"105","author":"MS Victoria","year":"2020","unstructured":"Victoria MS, Anna D, Kristina H, Daniela B, Ross J, Lisa K, et al. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica. 2020;105:2150\u201363.","journal-title":"Haematologica"},{"key":"7942_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Moore VDG, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"7942_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer cell. 2007;12:171\u201385.","journal-title":"Cancer cell"},{"key":"7942_CR37","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/bloodadvances.2022007728","volume":"7","author":"EA Olesinski","year":"2023","unstructured":"Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, et al. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023;7:2917\u201323.","journal-title":"Blood Adv"},{"key":"7942_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/bjc.2016.49","volume":"114","author":"M Butterworth","year":"2016","unstructured":"Butterworth M, Pettitt A, Varadarajan S, Cohen GM. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114:638\u201341.","journal-title":"Br J Cancer"},{"key":"7942_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-023-00286-5","volume":"9","author":"I Cloete","year":"2023","unstructured":"Cloete I, Smith VM, Jackson RA, Pepper A, Pepper C, Vogler M, et al. Computational modeling of DLBCL predicts response to BH3-mimetics. NPJ Syst Biol Appl. 2023;9:23.","journal-title":"NPJ Syst Biol Appl"},{"key":"7942_CR40","doi-asserted-by":"publisher","first-page":"eabo2838","DOI":"10.1126\/scisignal.abo2838","volume":"16","author":"S Mitchell","year":"2023","unstructured":"Mitchell S, Tsui R, Tan ZC, Pack A, Hoffmann A. The NF-\u03baB multidimer system model: A knowledge base to explore diverse biological contexts. Sci Signal. 2023;16:eabo2838.","journal-title":"Sci Signal"},{"key":"7942_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01090-y","volume":"14","author":"R Norris","year":"2024","unstructured":"Norris R, Jones J, Mancini E, Chevassut T, Simoes FA, Pepper C, et al. Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data. Blood Cancer J. 2024;14:105.","journal-title":"Blood Cancer J"},{"key":"7942_CR42","doi-asserted-by":"crossref","unstructured":"Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W, et al. A single-cell atlas of diffuse large B cell lymphoma. Cell Rep. 2022;39:110713.","DOI":"10.1016\/j.celrep.2022.110713"},{"key":"7942_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nchembio.2178","volume":"12","author":"Y Bian","year":"2016","unstructured":"Bian Y, Li L, Dong M, Liu X, Kaneko T, Cheng K, et al. Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder. Nat Chem Biol. 2016;12:959\u201366.","journal-title":"Nat Chem Biol"},{"key":"7942_CR44","doi-asserted-by":"publisher","first-page":"E2888","DOI":"10.1073\/pnas.1715639115","volume":"115","author":"S Mitchell","year":"2018","unstructured":"Mitchell S, Roy K, Zangle TA, Hoffmann A. Nongenetic origins of cell-to-cell variability in B lymphocyte proliferation. Proc Natl Acad Sci. 2018;115:E2888\u2013E97.","journal-title":"Proc Natl Acad Sci"},{"key":"7942_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5334\/jors.151","volume":"5","author":"C Rackauckas","year":"2017","unstructured":"Rackauckas C, Nie Q. Differentialequations. jl\u2013a performant and feature-rich ecosystem for solving differential equations in julia. J open Res Softw. 2017;5:15.","journal-title":"J open Res Softw"},{"key":"7942_CR46","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.18632\/oncotarget.2128","volume":"5","author":"YN Demchenko","year":"2014","unstructured":"Demchenko YN, Brents LA, Li Z, Bergsagel LP, McGee LR, Kuehl MW. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. Oncotarget. 2014;5:4554.","journal-title":"Oncotarget"},{"key":"7942_CR47","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.tranon.2018.07.007","volume":"11","author":"W Deng","year":"2018","unstructured":"Deng W, Clipson A, Liu H, Huang Y, Dobson R, Wang M, et al. Variable responses of MYC translocation positive lymphoma cell lines to different combinations of novel agents: impact of BCL2 family protein expression. Transl Oncol. 2018;11:1147\u201354.","journal-title":"Transl Oncol"},{"key":"7942_CR48","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2012.358","volume":"27","author":"H Quentmeier","year":"2013","unstructured":"Quentmeier H, Amini RM, Berglund M, Dirks WG, Ehrentraut S, Geffers R, et al. U-2932: two clones in one cell line, a tool for the study of clonal evolution. Leukemia. 2013;27:1155\u201364.","journal-title":"Leukemia"},{"key":"7942_CR49","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1038\/onc.2010.248","volume":"29","author":"JM Tromp","year":"2010","unstructured":"Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, et al. Dichotomy in NF-\u03baB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering. Oncogene. 2010;29:5071\u201382.","journal-title":"Oncogene"},{"key":"7942_CR50","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/bloodadvances.2024012706","volume":"8","author":"HY Estupi\u00f1\u00e1n","year":"2024","unstructured":"Estupi\u00f1\u00e1n HY, Bouderlique T, He C, Bergl\u00f6f A, Cappelleri A, Frengen N, et al. In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function. Blood Adv. 2024;8:1981\u201390.","journal-title":"Blood Adv"},{"key":"7942_CR51","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.20080238","volume":"205","author":"C Homig-Holzel","year":"2008","unstructured":"Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, M\u00fcller W, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-\u03baB pathway and promotes lymphomagenesis. J Exp Med. 2008;205:1317\u201329.","journal-title":"J Exp Med"},{"key":"7942_CR52","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.celrep.2014.07.037","volume":"8","author":"B Zhao","year":"2014","unstructured":"Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfeld H, et al. The NF-\u03baB genomic landscape in lymphoblastoid B cells. Cell Rep. 2014;8:1595\u2013606.","journal-title":"Cell Rep"},{"key":"7942_CR53","doi-asserted-by":"crossref","unstructured":"Zou Z, Ohta T, Oki S. ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data. Nucleic Acids Res. 2024;52:W45-53.","DOI":"10.1093\/nar\/gkae358"},{"key":"7942_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?. Hematol Am Soc Hematol Educ Program. 2016;2016:366\u201378.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"7942_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2278-330X.126531","volume":"3","author":"LS Raut","year":"2014","unstructured":"Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3:66\u201370.","journal-title":"South Asian J Cancer"},{"key":"7942_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/cells7090115","volume":"7","author":"JA Prescott","year":"2018","unstructured":"Prescott JA, Cook SJ. Targeting IKK\u03b2 in cancer: challenges and opportunities for the therapeutic utilisation of IKK\u03b2 inhibitors. Cells. 2018;7:115.","journal-title":"Cells"},{"key":"7942_CR57","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11:941.","journal-title":"Cell Death Dis"},{"key":"7942_CR58","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 A-M, Renders S, Stumpf K, Reyneri C, Betz B, et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov. 2023;13:1408\u201327.","journal-title":"Cancer Discov"},{"key":"7942_CR59","first-page":"471","volume":"126","author":"JA Woyach","year":"2015","unstructured":"Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood J Am Soc Hematol. 2015;126:471\u20137.","journal-title":"Blood J Am Soc Hematol"},{"key":"7942_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-98","volume":"14","author":"H Liu","year":"2014","unstructured":"Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie L, et al. Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer. 2014;14:98.","journal-title":"BMC Cancer"},{"key":"7942_CR61","doi-asserted-by":"publisher","first-page":"638897","DOI":"10.3389\/fonc.2021.638897","volume":"11","author":"N Faumont","year":"2021","unstructured":"Faumont N, Taoui O, Collares D, Jais J-P, Leroy K, Pr\u00e9vaud L, et al. C-rel is the pivotal NF-\u03baB subunit in germinal center diffuse Large b-cell lymphoma: a LYSA study. Front Oncol. 2021;11:638897.","journal-title":"Front Oncol"},{"key":"7942_CR62","first-page":"33","volume":"136","author":"T Liu","year":"2020","unstructured":"Liu T, Xu F, Thieme E, Lam V, Fan G, Nikolaenko L, et al. Pharmacologic targeting MCL1 with AZD5991 induces apoptosis and mitochondrial dysfunction in non-Hodgkin lymphoma (NHL) cells. Blood. 2020;136:33.","journal-title":"Blood"},{"key":"7942_CR63","doi-asserted-by":"crossref","unstructured":"Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O\u2019Brien S, et al. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed\/Refractory Hematologic Malignancies. Clinical Cancer Res. 2024;30:4844\u201355.","DOI":"10.1158\/1078-0432.CCR-24-0028"},{"key":"7942_CR64","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"VDG Moore","year":"2013","unstructured":"Moore VDG, Letai A. BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202\u20135.","journal-title":"Cancer Lett"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07942-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:44:09Z","timestamp":1757393049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7942"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07942-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.30.626166","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YL is a shareholder of DeepKinase Biotechnologies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPETING INTERESTS"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal work was performed according to guidelines from the University of California, Los Angeles under approved ARC protocols (B-14-110 for breeding and R-14-126 for experiment).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"620"}}